Alexion Pharmaceuticals (NASDAQ:ALXN) Cut to “Outperform” at UBS Group

UBS Group lowered shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from a strong-buy rating to an outperform rating in a research note published on Thursday, January 4th, The Fly reports.

Other equities analysts have also issued research reports about the company. SunTrust Banks reiterated a buy rating and set a $180.00 target price (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Deutsche Bank reiterated a buy rating and set a $158.00 target price (up previously from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. BMO Capital Markets reiterated an outperform rating and set a $173.00 target price (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Leerink Swann reiterated a buy rating and set a $169.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, December 6th. Finally, Piper Jaffray Companies reiterated an overweight rating and set a $170.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $154.00.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded up $1.02 during trading hours on Thursday, reaching $122.48. The company’s stock had a trading volume of 1,571,700 shares, compared to its average volume of 2,245,100. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $27,410.00, a price-to-earnings ratio of 54.68, a price-to-earnings-growth ratio of 1.03 and a beta of 1.17. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.32 by $0.12. The firm had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a return on equity of 3.51% and a net margin of 9.08%. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.23 earnings per share. equities research analysts forecast that Alexion Pharmaceuticals will post 4.82 earnings per share for the current fiscal year.

In related news, CEO Ludwig Hantson sold 2,553 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the sale, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 4.35% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Rathbone Brothers plc raised its position in Alexion Pharmaceuticals by 2.5% during the 2nd quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 50 shares during the last quarter. Evercore Wealth Management LLC raised its position in shares of Alexion Pharmaceuticals by 8.1% in the 2nd quarter. Evercore Wealth Management LLC now owns 1,665 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 125 shares in the last quarter. Wealthsource Partners LLC raised its position in shares of Alexion Pharmaceuticals by 4.4% in the 2nd quarter. Wealthsource Partners LLC now owns 3,002 shares of the biopharmaceutical company’s stock worth $365,000 after acquiring an additional 126 shares in the last quarter. National Asset Management Inc. raised its position in shares of Alexion Pharmaceuticals by 5.1% in the 2nd quarter. National Asset Management Inc. now owns 3,345 shares of the biopharmaceutical company’s stock worth $407,000 after acquiring an additional 162 shares in the last quarter. Finally, Tudor Investment Corp ET AL raised its position in shares of Alexion Pharmaceuticals by 2.4% in the 2nd quarter. Tudor Investment Corp ET AL now owns 7,207 shares of the biopharmaceutical company’s stock worth $877,000 after acquiring an additional 170 shares in the last quarter. 94.26% of the stock is owned by institutional investors and hedge funds.

WARNING: This report was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://ledgergazette.com/2018/01/12/alexion-pharmaceuticals-alxn-downgraded-to-outperform-at-ubs-group.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

The Fly

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply